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ORIGINAL ARTICLE
Purtscher-like Retinopathy Associated with Systemic
Lupus Erythematosus
Paradee Kunavisarut, MD1, Kessara Pathanapitoon, MD, PhD1, and
Aniki Rothova, MD, PhD2
1Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand and
2Department of Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands
ABSTRACT
Purpose: To report on clinical manifestations of Purtscher-like retinopathy (PLR) associated with systemic lupus
erythematosus (SLE) and visual outcomes.
Methods: We performed a retrospective cohort study of 11 patients (21 affected eyes) with PLR in SLE.
Results: All patients were treated with systemic corticosteroids ± immunosuppressive agents. Ocular therapy
included intravitreal injections with bevacizumab in 18/21 eyes and posterior sub-Tenon injections with
triamcinolone acetonide 13/21 eyes. Panretinal photocoagulation (PRP) was performed in 19/21 eyes and pars
plana vitrectomy was required in 5/21 eyes. Visual improvement was found at follow-up of 3 and 6 months
(p= 0.05). Poor visual outcome was associated with presence of neovascularizations at onset (p= 0.009),
development of vitreous hemorrhage during PRP (p= 0.015), and active status of SLE after onset of PLR (p= 0.029).
Conclusions: PLR might manifest as a devastating complication of SLE. We recommend treating any systemic
activity of SLE and starting an early ocular treatment.
Keywords: Bevacuzimab, complication, purtscher-like retinopathy, systemic lupus erythematosus, treatment
Purtscher’s retinopathy is a clinical syndrome char-
acterized by ischemic changes of the posterior pole
associated with multiple areas of whitening of inner
retina (Purtscher flecken), optic disc swelling, cotton
wool spots, and hemorrhages usually concentrated
around the optic disc. Purtscher’s retinopathy is a
mostly bilateral disorder and was originally described
after various types of trauma. Pathogenesis of this
syndrome was attributed to embolic occlusions of the
precapillary arterioles and/or impaired venous return
from raised intracranial/intrathoracic pressure and
secondary extravasation of fluid.1–3
Purtscher-like retinopathy (PLR) represents a clin-
ical syndrome with manifestations similar to the
original Purtscher’s retinopathy but related to causes
other than trauma.3 PLR was reported in various
conditions such as acute pancreatitis,4–6 fat embo-
lism,7 chronic renal failure,8 hemolytic uremic syn-
drome,9,10 after childbirth,11 weight lifting,12 battered
child syndrome,13 and several autoimmune dis-
eases.14,15 The visual prognosis of PLR in general is
poor and the secondary development of neovascular-
izations and glaucoma might even destroy the eye.
Herein we report on PLR in 11 patients with
systemic lupus erythematosus (SLE) and refer to its
management and visual outcomes.
MATERIALS AND METHODS
In this series we included 11 consecutive patients with
PLR associated with SLE from the ophthalmological
department of Chiang Mai University Hospital in
Thailand between September 2006 and September
2012. We performed a retrospective study of their
clinical, laboratory, and imaging data. We registered
clinical ocular manifestations, development of visual
acuity (VA) over time, complications, and SLE activity,
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as well as systemic and ocular treatment regimens
employed. Mean follow-up time was 19 months
(median 10 months; SD 20.051; range 3–72 months).
The diagnosis of SLE was based on the American
College of Rheumatology criteria in all cases.16 The
SLE disease activity was determined using the MEX-
SLEDAI score.17 PLR was defined as ischemia of
the posterior pole associated with multiple areas of
whitening of inner retina with optic disc swelling,
cotton wool spots, and hemorrhages in the absence of
previous trauma.
All patients were treated with a combination of
systemic (oral or intravenous corticosteroids, some-
times with addition of other immunosuppressive
agents) and local treatment (posterior sub-Tenon
corticosteroid and/or anti-vascular endothelial
growth factor (anti-VEGF) intraocular injections,
panretinal photocoagulation, and occasionally pars
plana vitrectomy), depending on the clinical condition
of the patients. First, we attempted to control the
activity of systemic SLE and PLR with a combination
of systemic and local treatment, then we applied anti-
VEGF injections in patients with neovascularizations,
large areas of nonperfusion on fluorescein angiogra-
phy (FA), and/or macular edema. Panretinal photo-
coagulation (PRP) was performed in all cases with
neovascularizations and/or large area of nonperfu-
sion on FA. Pars plana vitrectomy (PPV) was
performed in cases resistant to the above indicated
treatment or in patients with vitreous hemorrhage.
During follow-up, all patients were regularly
evaluated by gonioscopy for the presence of
neovascularizations.
We defined the progression of PLR as the ongoing
development of one or more of following character-
istics: retinal neovascularization, vitreous hemor-
rhage, neovascular glaucoma, progression of retinal
ischemic areas, and increase of macular edema.
Stabilization of PLR was defined as a situation in
which no progression occurred and hemorrhages and
neovascularizationd diminished.
For all calculations with VA data, we converted
Snellen VA to the logarithm of the minimum angle of
resolution (logMAR). For easier understanding the
logMAR results were converted back to Snellen VA
and presented in this report. We included only right
eyes of affected patients for all calculations to prevent
the bias of similar manifestations in bilateral cases.
This study was approved by a suitably constituted
ethics committee of the institution within which the
work was undertaken and conforms to the provisions
of the Declaration of Helsinki.
RESULTS
General characteristics of the patients are given
in Table 1. All patients except one were females
(10/11 patients; 91%) with a mean age of 31 years
(median 29 years; SD 9.792; range 15–44 years). Before
the onset of PLR, 5/11 (45%) patients were already
known to have SLE and the remaining 6/11 (55%)
were diagnosed with SLE after the onset of PLR.
At the time of PLR onset, active SLE was observed
in 7/11 patients (64%) and the remaining 4 were
considered to be in the inactive stage. Anticardiolipin
antibodies were positive only in 1 patient (9.5%).
None had additional risk factors for retinal ischemia,
such as diabetes mellitus, hypertension, dyslipidemia,
or nephropathy.
Bilateral ocular involvement was present in 10/11
(91%) patients, resulting in 21 affected eyes. FA was
performed in 9/11 patients (out of 2 missing cases,
one had known allergy to fluorescein and the other
had dense vitreous hemorrhages, which prevented
view of the fundus). Macular ischemia and a
nonperfusion area of more than 10 disc diameters
were noted at onset in 16/18 (89%) evaluable eyes
(Figures 1, 2). Retinal neovascularization at initial
presentation was demonstrated in 4/11 (36%) patients
(7/21; 33% affected eyes).
After the onset of PLR, all patients were treated
with systemic steroids (1 mg/kg/day), and additional
immunosuppressive treatment was initiated in 6
patients, resulting in 7 patients being on immunosup-
pressive therapy (Table 2). Severe systemic complica-
tions caused by either SLE or its treatment developed
in 3 patients (sepsis in all, Table 2).
Ocular treatment included intravitreal injections
with bevacizumab (Avastin 1.25 mg/0.05 mL) and
posterior sub-Tenon injections with triamcinolone
acetonide (Kenakort 20 mg/0.5 mL) (18/21; 86% and
13/21; 62% of affected eyes, respectively). Panretinal
photocoagulation (PRP) was performed in 19/21
(91%) of affected eyes. Pars plana vitrectomy (PPV)
was performed in 4 patients; 5/21 (24%) of affected
eyes, which was 1/5 eyes (case 7), had severe vitreous
hemorrhage at the initial presentation.
With a combined systemic and ocular treatment,
the progression of PLR was stopped in all patients.
There were 2/11 patients (18%; 4/21 affected eyes,
TABLE 1. General features of 11 patients with Purtscher-like
retinopathy associated with systemic lupus erythematosus.
Median age (years) 29.0 (range 15–44)
Female gender 10 (91%)
Bilateral involvement 10 (91%)
Known with SLE before the
onset of PLR
5 (45%)
Active systemic SLE at onset of PLR 7 (64%)
Systemic medication at onset of PLR 6 (55%)
Positive anticardiolipin antibodies 1 (9.5%)
Median ESR 56.0 range (16–118)
Median follow-up time (months) 10.0 range (3–72)
SLE, systemic lupus erythematosus; PLR, Purtscher-like retino-
pathy; ESR, erythrocyte sediment rate.
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FIGURE 1. Ocular manifestations of Purtscher-like retinopathy associated with systemic lupus erythematosus (Table 2, case 2). (A, B)
Fundus photographs of both eyes at presentation demonstrate extensive cotton wool spots and occlusions of multiple arterioles,
including the macular area, which exhibits cherry red spots. (C–F) Fundus photographs and fluorescein angiography at 3 months
follow-up, after treatment with oral prednisolone and cyclophosphamide, the cotton wool spots subsided but disc and retinal
neovascularizations developed. Fundus fluorescein angiography shows extensive ischemia involving macula and neovasculariza-
tions. (G, H) Fundus photographs at 9 months follow-up. After panretinal laser photocoagulation as well as intraocular injections with
bevacizumab, the neovascularizations regressed and the situation stabilized with bilateral pale optic discs.
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FIGURE 2. Ocular manifestations of Purtscher-like Retinopathy associated with systemic lupus erythematosus (Table 2, case 3). (A, B)
Fundus photographs of both eyes at presentation demonstrate extensive cotton wool spots and occlusions of multiple arterioles,
including macular area, which exhibits cherry red spots. (C, D) Fundus fluorescein angiography at 5 months follow-up, after
panretinal laser photocoagulation as well as intraocular injections with bevacizumab, shows large areas of nonperfusion, vascular
leakage, and macular ischemia without neovascularization. (E, F) Fundus photographs at 1 year follow-up, when retinal situation
became quiescent.
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19%) who stabilized within 3 months and 9 patients
(82%; 15/21 eyes; 71%) reached a stabilized situation
within 6 months. During PRP, vitreous hemorrhage
occurred in 4/11 patients (7/21 eyes, of whom 4
required PPV and additional laser coagulation), but
retinal detachments did not develop. Additional
complications included ocular hypertension in 3/11
patients (4/21 eyes), which could be controlled with
one or two topical anti-glaucoma medications, but
none of the patients developed neovascular glaucoma.
At onset, visual acuity (VA) of less than 0.1 was
found in the majority of patients (8/11; 73%; 14/21;
67% eyes). At 6 months follow-up, VA of less 0.1 was
noted in 5/9 (56%) patients (8/17; 47% eyes). After
treatment, the most affected eyes (14/21; 67%) had
improved visual acuity while 4/21 (19%) had stable
VA and 3/21 (14%) decreased. While we observed
significant visual improvement at 3 and 6 months of
follow-up (p= 0.05, Wilcoxon signed rank test), the
number of eyes with VA of less than 0.1 at onset and at
6 months follow-up did not differ (14/21; 67% versus
8/17, 47%, p= 0.324). VA of less than 0.1 at 6 months
follow-up was associated with following character-
istics: the presence of neovascularization at onset of
PLR (p= 0.009 Fisher’s exact test), the development of
vitreous hemorrhage during PRP (p= 0.015 Fisher’s
exact test), and active status of SLE after the onset of
PLR (p= 0.029 Fisher’s exact test). No associations
were observed between the visual outcomes and
activity of SLE at onset of PLR, medications at onset,
presence of anticardiolipin antibodies, treatment with
immunosuppressive agents, area of nonperfusion,
presence of macular ischemia, and initial VA.
Since our treatment induced stabilization in all
eyes, oral prednisolone medication could be gradually
decreased and/or tapered off in all patients. Six out of
11 patients could stop prednisolone medication
entirely (mean 21 months; median 13 months; range
8–60 months) and the remainder could decrease their
daily dosage. During the follow-up, 3 out of 11
patients developed sepsis at various intervals after
the onset of PLR (Table 2) and 1 of these patients died.
The septic periods developed at variable times after
the onset of PLR in patients with different therapeutic
regimens and, moreover, 1 patient suffered from
septic phases even before the onset of PLR.
DISCUSSION
We report on severe PLR in 11 patients with SLE and
point out that stabilization of PLR occurred in all cases
with a combination of systemic and local treatment
regimens. All but 1 patient had bilateral PLR and a
majority of patients (73%) had visual acuity at onset of
less than 0.1. During follow-up, none of the patients
developed retinal detachment or neovascular glau-
coma, which might be caused by an aggressive
treatment including the early local application of
bevacizumab.
Ocular complications of SLE are generally asso-
ciated with active systemic disease and the pathogenic
mechanism of the SLE retinopathy has been attributed
to the immune complex-mediated vasculopathy.18–20
Therefore, control of the systemic disease is a primary
goal of the treatment. The aggressive immunosup-
pression was recommended, which seemed to
improve the systemic disease and the status of
retinopathy but visual outcome was generally unaf-
fected due to persistent arteriolar attenuation and
subsequent progression of retinal vascular occlu-
sions.21–24
Ischemia and neovascularizations in PLR were
regularly reported (in our series illustrated in
Figure 1 of case 2) resulting in very poor visual
outcomes. Miguel et al. and Sellami et al. compared
the visual outcomes of PLR of diverse origins and
concluded that SLE-associated PLR had worst visual
acuity at presentation (1.7 logMAR) and did not
improve with corticosteroid treatment.15,25 Previously,
approximately 50% of SLE patients with PLR had
visual acuity less than 6/20.26–29 Jabs et al.21 reported
on this potentially visually devastating form of
retinopathy in SLE in 11 patients (20 involved eyes)
and noted the very poor visual outcomes despite the
use of different regimens of immunosuppressive
drugs, including oral and intravenous corticosteroids,
azathioprine, and cyclophosphamide. In his series
from the pre-anti VEGF era, approximately 50% of
involved eyes had visual acuity less than 6/60, and
45% developed vitreous hemorrhage, which is closely
similar to our study (47 and 38%, respectively). In
contrast to our series, the authors also observed
retinal detachment in 3 eyes (15%), and 1 additional
eye (5%) developed ischemia of anterior eye segment.
The severity of PLR in our patients seems to be similar
to that in previous reports, but might have been also
influenced by a late presentation since one-third of the
affected eyes had already retinal neovascularizations
at first presentation to ophthalmologist. Despite this
severe initial presentation, the retinal manifestations
stabilized in all patients and lacked severe complica-
tions such as neovascular glaucoma, retinal detach-
ment, and anterior segment ischemia.
The role of bevacizumab may explain this differ-
ence in outcome. Bevacizumab induces temporary
decrease of VEGF levels and reduces retinal non-
perfusion, which might cover the time interval until
the PRP became effective. Campochiaro et al.30 found
that high levels of VEGF result in worsening of retinal
ischemia and progressive retinal nonperfusion,
including the macular area. Therefore, anti-VEGF
medications can reduce the total amount of retinal
nonperfusion/macular edema and counteract the
neovascular complications.30 Obviously, bevacizumab
cannot restore the obliteration of the arteries involved
Purtscher-like Retinopathy Associated with SLE 65
! 2016 Taylor & Francis Group, LLC
and the visual outcome remains dependent of
macular ischemic changes (Figure 3, case 11).
Aggressive treatment of SLE has effectively
reduced the mortality related to disease activity but
also has led to the occurrence of complications that
can be related to disease itself or to adverse effects
of treatment, especially infections related to severe
immunosuppression. Mortality rates in SLE cohorts
with follow-up periods ranging from 8 to 14 years
varied from 6.8 to 20.2%.31–34 The reported causes
of death from SLE differ widely. While some studies
reported that activity of SLE represented a major
cause of death,35–37 others found that infections were
more common.34,38–42 However, most patients
who died from infections also had active SLE. Our
3 patients who developed sepsis received different
therapeutic regimens and it was not possible to
conclude whether sepsis developed due to severe
active SLE or due to its treatment. Two patients had
septic periods already before the start of immuno-
suppressive treatment and moreover developed septic
stage during the decreasing medications a long time
after the onset of PLR. One patient, however, devel-
oped sepsis 10 days after the initiation of azathioprine
treatment given because of PLR. In a study of 349
Thai patients with SLE, the patients with infection-
related and not infectious causes of death did not
differ in the dosages of both prednisolone and/or
cyclophosphamide.34
The retrospective nature of the study and the
absence of a control group constitute the drawbacks of
our study. Based on our results it is difficult to prove
FIGURE 3. Ocular manifestations of Purtscher-like retinopathy associated with systemic lupus erythematosus (Table 2, case 11). (A–D)
Fundus photographs and optical coherence tomography at presentation exhibit cotton wool spots, hemorhages together with bilateral
macular edema. (E, F) Optical coherence tomography 3 weeks after intravitreal bevacizumab injection demonstrates the resolution of
macular edema. During an additional 3 months follow-up, macular edema did not recur but visual acuity did not improve due to
macular ischemia.
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that combination of systemic and aggressive ocular
treatment including bevacizumab injection can stop
the progression of PLR. However, case-control or
randomization trials will probably not be feasible in
the uncommon SLE complication. However, the
stabilization of PLR and absence of neovascular
glaucoma suggest that our treatment approach
might be effective.
We conclude that PLR might manifest as a
devastating ocular complication of SLE and recom-
mend treating the systemic SLE activity in all affected
patients and starting an early local treatment with
anti-VEGF medications and PRP in order to retain as
much useful vision as possible.
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